Combination therapy targets latent reservoir of HIV

(Beth Israel Deaconess Medical Center) In a new study, Dan H. Barouch, MD, PhD, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, and colleagues demonstrate that administering broadly neutralizing antibodies (bNAb) designed to target HIV in combination with agents that stimulate the innate immune system delayed viral rebound following discontinuation of ART in monkeys. The findings suggest that this two-pronged approach represents a potential strategy for targeting the viral reservoir.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news